1-4 of 4
Dan Jones, Ph.D.
Close
Sort by
Journal Articles

Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Dan Jones, Ph.D., Susan O’Brien, M.D., Mary Beth Rios, Jorge Cortes, M.D.
Journal: Blood
Blood (2007) 110 (11): 2961.
https://doi.org/10.1182/blood.V110.11.2961.2961
Published: 2007
Journal Articles

Dynamics of BCR-ABL1 Transcripts during Dasatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Dan Jones, Ph.D., Mary Beth Rios, Susan O’Brien, M.D., Jorge Cortes, M.D.
Journal: Blood
Blood (2007) 110 (11): 2962.
https://doi.org/10.1182/blood.V110.11.2962.2962
Published: 2007
Journal Articles

Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Farhad Ravandi-Kashani, M.D., William Wierda, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 4752.
https://doi.org/10.1182/blood.V104.11.4752.4752
Published: 2004
Journal Articles

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Srdan Verstovsek, M.D., Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 1007.
https://doi.org/10.1182/blood.V104.11.1007.1007
Published: 2004